COMMUNIQUÉS West-GlobeNewswire

ORYZON Updates on New Activities
23/09/2019
To present at upcoming international conference - ESMO-2019 in Barcelona, Spain - 19th Annual Biotech in Europe Investment Forum in Basel, Switzerland - 4th Annual MarketsandMarkets Epigenetics Congress in London, UK - [...]
Entera Bio Reports Positive Results from a Phase 2 PK/PD Study of Oral PTH (1-34) in Patients with Hypoparathyroidism
23/09/2019
Results of a Phase 2 PK/PD study of Oral PTH (1-34) in patients with hypoparathyroidism were presented at the American Society for Bone and Mineral Research Annual Meeting Data suggest favorable pharmacologic and [...]
Synthorx to Present at the European Society for Medical Oncology (ESMO) 2019 Congress
23/09/2019
SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced that preclinical [...]
Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D. and Re-Appointment of Andy Sassine to the Board of Directors
23/09/2019
SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (“Arcturus Therapeutics”) (NASDAQ: ARCT), a leading messenger RNA medicines company focused on the discovery, development and [...]
ALR Technologies Creates Algorithm to Support Therapy Advancement for Non-Insulin Dependent (NID) Diabetes Patients
23/09/2019
ALRT’s comprehensive diabetes management system now provides decision support for healthcare providers treating non-insulin dependent type 2 diabetes patients RICHMOND, Va., Sept. 23, 2019 (GLOBE NEWSWIRE) -- ALR [...]
Immutep to Receive £4M Milestone Payment From GSK
23/09/2019
SYDNEY, Australia, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune [...]
Qrons Announces Appointment of Derrick Chambers to Advisory Board
23/09/2019
Former NFL Player is Financial Literacy Advocate to NFL Players Association and NFL Alumni Association NEW YORK, NY, Sept. 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Qrons Inc. (OTCQB: QRON), an emerging [...]
AMAG Files Definitive Consent Revocation Statement and Sends Letter to Shareholders
23/09/2019
Details Caligan Partners’ Reckless Business Ideas and Inexperienced Director Nominees Urges Shareholders to Sign and Return AMAG’s GREEN Consent Revocation Card WALTHAM, Mass., Sept. 23, 2019 (GLOBE NEWSWIRE) -- AMAG [...]
CareDx’s KidneyCare iBox Technology Clinically Validated in BMJ Publication
23/09/2019
Artificial Intelligence algorithm predicts long-term kidney transplant outcomes BRISBANE, Calif., Sept. 23, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the [...]
Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation (CF Foundation) To Provide Funding and Support for ELX-02 U.S. Phase 2 Clinical Trial
23/09/2019
CF Foundation and Eloxx to form joint program advisory group focused on the development of ELX-02 for cystic fibrosis Eloxx plans to conduct the U.S. portion of the Phase 2 clinical trial at Cystic Fibrosis Therapeutics [...]
Avadel Pharmaceuticals Announces FDA Agreement to Reduce the Sample Size for the Ongoing Pivotal Phase 3 Study for Once-Nightly FT218; Full Enrollment Now Expected by End of 2019
23/09/2019
FDA agrees with Company’s proposed changes to the statistical analysis plan for the REST-ON Phase 3 study for once-nightly sodium oxybate, FT218 Reduces estimated time to completion by up to 12 months; now expected to [...]
First Data On Combination Of Enlivex’s Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Revealed At The Joint IIS-ISCR Special 2019 Conference
23/09/2019
Nes-Ziona, Israel, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq:ENLV), a clinical-stage immunotherapy company, today announced the first presentation of its preclinical studies, which were [...]
TG Therapeutics Announces Data Presentations at the XVIII International Workshop on Chronic Lymphocytic Leukemia (iwCLL)
23/09/2019
Phase 2 study of umbralisib monotherapy in BTK/PI3K-delta intolerant CLL reports an estimated median progression-free survival (PFS) of 23.5 months (n=50) with 58% of patients on umbralisib longer than their prior [...]
ADMA Biologics to Present at 2019 Cantor Global Healthcare Conference
23/09/2019
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 23, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin [...]
BioCryst Appoints Helen Thackray, M.D., to Board of Directors
23/09/2019
RESEARCH TRIANGLE PARK, N.C., Sept. 23, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed clinical rare disease expert, Helen Thackray, M.D., FAAP, to [...]
Athenex Completes Construction of New API Facility in Chongqing
23/09/2019
BUFFALO, N.Y., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
Athenex to Present at the 2019 San Antonio Breast Cancer Symposium
23/09/2019
BUFFALO, N.Y., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
Athenex to Highlight Oral Paclitaxel Clinical Programs Targeting Various Solid Tumors at the ESMO Congress 2019
23/09/2019
BUFFALO, N.Y., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
Akcea Announces CEO Transition and Elects Two New Board Members
23/09/2019
Damien McDevitt, Ph.D. appointed interim CEO; Michael Yang and Joseph ‘Skip’ Klein join Board of Directors BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate [...]

Pages